Accession Number : AD1018495


Title :   Efficacy of the Direct Instruction Language for Learning (DI-LL) Program to Promote Expressive and Receptive Language in Children with Autism Spectrum Disorder


Descriptive Note : Technical Report,15 Jun 2015,14 Jun 2016


Corporate Author : Emory University Atlanta United States


Personal Author(s) : Scahill,Lawrence ; Shillingsberg,M A ; Bowen,Crystal ; Badura,Marc


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/1018495.pdf


Report Date : 01 Jul 2016


Pagination or Media Count : 7


Abstract : Available information indicates that as many as 75 of children with autism spectrum disorder (ASD) have language delay ranging from mild to severe. Many interventions have been developed to address language delay including intensive treatment using applied behavior analysis (ABA). Although often effective for severe language delay (e.g., children with no language),intensive ABA intervention may not be needed for children with moderate language delay. Untreated moderate language delay predictably interferes with the child's ability to advance in the social and academic domains. Direct Instruction Language for Learning (DI-LL) is a highly structured intervention with empirical support in children with language delay uncomplicated by autism spectrum disorder. However, DI-LL has not yet been carefully studied in children with ASD. As in ABA, the DI-LL curriculum incorporates immediate reinforcement for correct responses, immediate and systematic error correction procedures, shaping, prompting, and fading. To date, there is only one small study of DI-LL in children with ASD and language delay. The purpose of this study is to test the efficacy of DI-LL in a six-month randomized trial in 100 children with ASD and moderate language delay. Eligible subjects will be randomly assigned to DI-LL or Treatment As Usual (TAU) for 6 months.


Descriptors :   BEHAVIOR , BRAIN , BRAIN FUNCTION IMPAIRMENT , MENTAL DISORDERS , language , Social communication , intervention , therapeutics , clinical trials , learning , training


Distribution Statement : APPROVED FOR PUBLIC RELEASE